339 related articles for article (PubMed ID: 17582205)
1. A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy.
Hamada Y; Fukagawa M
Kobe J Med Sci; 2007; 53(1-2):53-61. PubMed ID: 17582205
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of thioredoxin1 in transgenic mice suppresses development of diabetic nephropathy.
Hamada Y; Miyata S; Nii-Kono T; Kitazawa R; Kitazawa S; Higo S; Fukunaga M; Ueyama S; Nakamura H; Yodoi J; Fukagawa M; Kasuga M
Nephrol Dial Transplant; 2007 Jun; 22(6):1547-57. PubMed ID: 17360766
[TBL] [Abstract][Full Text] [Related]
3. Thioredoxin-Interacting Protein Deficiency Protects against Diabetic Nephropathy.
Shah A; Xia L; Masson EA; Gui C; Momen A; Shikatani EA; Husain M; Quaggin S; John R; Fantus IG
J Am Soc Nephrol; 2015 Dec; 26(12):2963-77. PubMed ID: 25855771
[TBL] [Abstract][Full Text] [Related]
4. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression.
Akahori H; Ota T; Torita M; Ando H; Kaneko S; Takamura T
J Pharmacol Exp Ther; 2005 Aug; 314(2):514-21. PubMed ID: 15857946
[TBL] [Abstract][Full Text] [Related]
5. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation.
Usui HK; Shikata K; Sasaki M; Okada S; Matsuda M; Shikata Y; Ogawa D; Kido Y; Nagase R; Yozai K; Ohga S; Tone A; Wada J; Takeya M; Horiuchi S; Kodama T; Makino H
Diabetes; 2007 Feb; 56(2):363-72. PubMed ID: 17259380
[TBL] [Abstract][Full Text] [Related]
6. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model.
Meier M; Park JK; Overheu D; Kirsch T; Lindschau C; Gueler F; Leitges M; Menne J; Haller H
Diabetes; 2007 Feb; 56(2):346-54. PubMed ID: 17259378
[TBL] [Abstract][Full Text] [Related]
7. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy.
Mizuno S; Nakamura T
Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594
[TBL] [Abstract][Full Text] [Related]
8. Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress.
Hamada Y; Kitazawa S; Kitazawa R; Fujii H; Kasuga M; Fukagawa M
Bone; 2007 May; 40(5):1408-14. PubMed ID: 17251074
[TBL] [Abstract][Full Text] [Related]
9. Tranilast attenuates the up-regulation of thioredoxin-interacting protein and oxidative stress in an experimental model of diabetic nephropathy.
Tan SM; Zhang Y; Cox AJ; Kelly DJ; Qi W
Nephrol Dial Transplant; 2011 Jan; 26(1):100-10. PubMed ID: 20573806
[TBL] [Abstract][Full Text] [Related]
10. Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property.
Nam SM; Lee MY; Koh JH; Park JH; Shin JY; Shin YG; Koh SB; Lee EY; Chung CH
Diabetes Res Clin Pract; 2009 Feb; 83(2):176-82. PubMed ID: 19111363
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
Russo LM; del Re E; Brown D; Lin HY
Diabetes; 2007 Feb; 56(2):380-8. PubMed ID: 17259382
[TBL] [Abstract][Full Text] [Related]
12. Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats.
Jeong KH; Lee TW; Ihm CG; Lee SH; Moon JY; Lim SJ
Am J Nephrol; 2009; 29(3):274-82. PubMed ID: 18812693
[TBL] [Abstract][Full Text] [Related]
13. Effects of eicosapentaenoic acid on the early stage of type 2 diabetic nephropathy in KKA(y)/Ta mice: involvement of anti-inflammation and antioxidative stress.
Zhang M; Hagiwara S; Matsumoto M; Gu L; Tanimoto M; Nakamura S; Kaneko S; Gohda T; Qian J; Horikoshi S; Tomino Y
Metabolism; 2006 Dec; 55(12):1590-8. PubMed ID: 17142129
[TBL] [Abstract][Full Text] [Related]
14. Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy.
Hou Y; Li S; Wu M; Wei J; Ren Y; Du C; Wu H; Han C; Duan H; Shi Y
Am J Physiol Renal Physiol; 2016 Mar; 310(6):F547-59. PubMed ID: 26719366
[TBL] [Abstract][Full Text] [Related]
15. Antioxidant SOD mimetic prevents NADPH oxidase-induced oxidative stress and renal damage in the early stage of experimental diabetes and hypertension.
Peixoto EB; Pessoa BS; Biswas SK; Lopes de Faria JB
Am J Nephrol; 2009; 29(4):309-18. PubMed ID: 18849601
[TBL] [Abstract][Full Text] [Related]
16. Halofuginone prevents extracellular matrix deposition in diabetic nephropathy.
Sato S; Kawamura H; Takemoto M; Maezawa Y; Fujimoto M; Shimoyama T; Koshizaka M; Tsurutani Y; Watanabe A; Ueda S; Halevi K; Saito Y; Yokote K
Biochem Biophys Res Commun; 2009 Feb; 379(2):411-6. PubMed ID: 19114027
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats.
Yuan J; Jia R; Bao Y
J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):118-26. PubMed ID: 17907099
[TBL] [Abstract][Full Text] [Related]
19. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
20. Effect of polysaccharides from Ganoderma lucidum on streptozotocin-induced diabetic nephropathy in mice.
He CY; Li WD; Guo SX; Lin SQ; Lin ZB
J Asian Nat Prod Res; 2006 Dec; 8(8):705-11. PubMed ID: 17145658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
